NCT02097082已完成不适用
An Evaluation of the 480 Biomedical STANZA™ Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
480 Biomedical14 个研究点 分布在 4 个国家目标入组 28 人开始时间: 2013年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 28
- 试验地点
- 14
- 主要终点
- Major Adverse Events
研究概览
简要总结
An evaluation of the safety and performance of the STANZA Drug-eluting Resorbable Scaffold (DRS) system for the treatment of patients with obstructive superficial femoral artery disease.
详细描述
The STANZA DRS system is comprised of a controlled release paclitaxel-eluting bioresorbable scaffold and a delivery system used in the treatment of superficial femoral artery disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Age > 18 years.
- •De novo stenotic lesion(s) in the superficial femoral artery located at least 1 cm distal to the femoral bifurcation and > 5 cm above the joint space of the knee.
- •Patient has symptomatic intermittent claudication affecting at least the target leg (Rutherford Class 2-3). Patients should have first received conservative medical management of their symptoms prior to study inclusion. The symptoms can be bilateral.
- •The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ethics committee of the respective clinical site.
- •The study patient agrees to comply with all required post-procedure study requirements.
- •Baseline Inclusion Criteria
- •Reference vessel diameter (RVD) 5.0 -6.0 mm measured by an objective measurement such as online Quantitative Vessel Analysis (QVA).
- •Target lesion length ≤ 90 mm; total occlusion length < 40 mm.
- •Target lesion has a ≥70% diameter stenosis.
- •Angiographic evidence of at least one runoff vessel to the ankle/foot without hemodynamically significant stenosis (>50% diameter stenosis) that does not require any treatment within 3 months of the index procedure.
- •Procedural access can be accomplished via contralateral vascular access or if antegrade access no closure device can be utilized and closure has to occur via manual pressure.
- •Patent common and external iliac: TASC A & B iliac lesions may be treated at the time of index procedure (before treatment of the target lesion) if residual stenosis is ≤30%.
排除标准
- •Previous vascular surgery/endovascular treatment of the target lesion.
- •Re-vascularization of target vessel within 30 days of study procedure.
- •Critical limb ischemia defined as Rutherford Becker Category 4-
- •Known coagulation disorders or intolerance or allergies to aspirin, clopidogrel or ticlopidine, heparin, any scaffold components, contrast agents which cannot be adequately pre-medicated.
- •Life expectancy ≤12 months.
- •Planned procedure that necessitates the discontinuation of antiplatelet medications used in conjunction with the investigational device within 3 months post-procedure.
- •Inability to walk due to orthopedic or other nonvascular complications.
- •Pregnancy or breast feeding or patient desires to become pregnant.
- •Non-atherosclerotic lesion (e.g. vasculitis).
- •Renal insufficiency (serum creatinine level > 220 µmol/L or > 2.5 mg/dl, or patient is on dialysis).
- •Patient has medical condition(s) which could affect study assessments or may adversely affect the safety and/or success of the study treatment.
- •Active systemic infection or lower limb infection of any nature.
- •White Blood Cells (WBC) ≤ 3,000 cells/mm
- •Myocardial infarction within 30 days prior to the study procedure.
- •Stroke within 90 days prior to the study procedure.
- •Uncontrolled atrial fibrillation.
- •Currently participating in an investigational drug or another device study. Note: Trials requiring extended follow-up for products that were investigational, but have since become commercially available, are not considered investigational trials.
- •Prior use of paclitaxel-eluting products in the target limb less than 6 months prior to index procedure.
- •Patient has known unstable angina.
- •Baseline Exclusion Criteria
- •Target lesion treatment with a drug eluting balloon.
- •Target lesion treatment with atherectomy, laser, or cryoplasty (use of a cutting or scoring balloon is permitted prior to scaffold implantation only).
- •Suspicion for or evidence of subintimal passage of guidewire.
- •Severely calcified lesion(s).
- •Target lesion which, based on two angiographic orthogonal views, exhibit a persistent balloon deformity during pre-dilatation with a nominally sized balloon.
- •Target vessel (superficial femoral artery) has an angiographically significant (> 50% diameter stenosis) lesion located distally or proximally to the target lesion.
- •Acute embolic complication following pre-dilatation.
- •Target vessel contains an acute thrombus.
- •Aneurysm in target vessel or co-existing clinically significant aneurysmal disease of the abdominal aorta, iliac or popliteal arteries.
- •Intervention in the infra-inguinal arteries outside of the target lesion.
- •Planned procedure within 30 days after the index procedure.
- •Positive pregnancy test for females of child bearing potential.
结局指标
主要结局
Major Adverse Events
时间窗: 30 days
Freedom from all causes of death, emergent endovascular intervention or surgical intervention on the target limb, index limb amputation.
Patency by Ultrasound
时间窗: through 6 months
Patency measured by duplex ultrasound with ≤50% restenosis (Peak Systolic Velocity Ratio (PSVR ≤ 2.4).
次要结局
- Technical Success(Procedure)
- Device Success(Procedure)
- Patency by Ultrasound(12, 24 months)
- Patency by Angiography(12 months)
- Surgical Intervention on the target limb, index limb amputation(3,6,12, and 24 months)
- Clinical Success(48 hours)
- Clinically Driven Target Lesion Revascularization (TLR)(6,12, 24 months)
研究者
研究点 (14)
Loading locations...
相似试验
招募中
不适用
Evaluation of the First, Second, and New Drug-Eluting Stents in Routine Clinical PracticePercutaneous Transluminal Coronary AngioplastyCoronary Artery DiseaseNCT01186133Seung-Jung Park50,000
招募中
不适用
Prospective Evaluation of Drug-Eluting Stents in Routine Clinical Practice (ASAN PCI Registry)Coronary Artery DiseaseNCT01788592Seung-Jung Park50,000
已完成
不适用
Treatment of Symptomatic Lumbar Internal Disc Disruption (IDD) With the Biostat® Disc Augmentation System: A Pilot StudyLow Back PainNCT00693784Spinal Restoration, Inc.15
终止
不适用
BIOFLOW-SV All Comers Registryde NovoSymptomatic Ischemic Heart DiseaseRestenoses, CoronaryNCT03600948Biotronik AG261
终止
不适用
BIOFLOW-SV Portugal RegistryIschemic Heart DiseaseNCT03600961Biotronik AG173